Short answer
MYRIAD GENETICS INC (MYGN) filed its Q3 2026 10-Q quarterly report on Nov 6, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $203M (down 1.5% year over year) with net income of −$44M.
Q3 2026 key financials · XBRL
- Revenue
- $203M
- −1.5% YoY · +6.3% QoQ
- Net income
- −$44M
- −60.2% YoY · −1.6% QoQ
- Operating margin
- -19.7%
- Gross margin
- 67.9%
- EPS (diluted)
- −$0.46
- −58.6% YoY · +0.0% QoQ
Source: XBRL data from the MYRIAD GENETICS INC (MYGN) Q3 2026 10-Q on SEC EDGAR. USD.
MYRIAD GENETICS INC Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $202.7M, down $3.0M YoY from $205.7M
- Cost-of-revenue margin 67.9% vs 69.9% YoY, with cost of revenue 32.1% vs 30.1%
- Best segment Mental Health, revenue $39.5M vs $38.7M; worst Prenatal Health, $39.3M vs $44.5M
- Cash $107.1M vs $149.6M at December 31, 2025, with operating cash use of $30.5M
- Prenatal Health sale for $210M plus inventory, expected closing early 2027; reimbursement pressure and coverage limitations remain headwinds
Risk Factors
- Newly added transaction risk: Prenatal Health sale to Laboratory Corporation of America for $210 million plus inventory remains subject to regulatory approvals
- Regulatory risk: Hart-Scott-Rodino and state healthcare clearances could delay, condition, or block closing
- Operational risk: Sale restrictions may limit Prenatal Business responses to market developments before closing
- Financial risk: Lower post-sale revenue base increases risk of breaching the Credit Agreement revenue covenant
- Liability risk: Myriad retains certain Prenatal billing, coding, reimbursement liabilities and indemnification obligations
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other MYRIAD GENETICS INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.